Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

We identify considerable upside potential for the Medtech & Services sector

After a period of heightened uncertainty, clear signs of economic normalization are emerging. This creates a supportive environment for the healthcare sector overall – particularly for Medtech & Services, where structural growth drivers and solid fundamentals continue to strengthen the outlook.
18.11.2025 - Marcel Fritsch
  • The Economy

    • The Fed lowered its target range for the federal funds rate by 0.25% to 3.75-4.00% on October 29, 2025
    • Core CPI was below Street expectations, although investors had anticipated a higher print due to new import tariffs
    • Over the past 3-4 months, the US labor market showed signs of a slowdown
    • In summary, the US economy seems to normalize which is a positive sign for the healthcare sector
  • The Healthcare sector

    • In Pharma, Pfizer and AstraZeneca reached US pricing deals aligned with the August executive order (EO) terms, including MFN Medicaid, DTC plan (TrumpRx), MFN for new launches, and US capex spend
    • In November, Eli Lilly and Novo Nordisk signed a pricing agreement with the US government for their weight loss drugs
    • Healthcare has outperformed the broader equity market by 9%¹
    • Odds remain intact for a potential ACA subsidy extension even after eight Democratic senators broke with their party to support the Republicans’ proposal to end the government shutdown
    • In 2026, the Trump Administration will likely refocus on the midterm elections scheduled for November 2026
    • In summary, investor sentiment toward healthcare has improved significantly over the past month
  • The Medtech & Services sector

    • Life Sciences Tools have benefited from Pharma pricing deals, with Thermo Fisher and Danaher outperforming by 24% and 17%, respectively ¹
    • The Medtech sector outperformed the broader equity market by 4% ¹
    • Strong product cycles and sustained surgical volumes drove earnings above 3Q expectations
    • Faster-growing Medtech and Life Sciences Tools names should benefit disproportionately from declining interest rates
    • Medtech, hospital and selected health insurance companies would benefit from an extension of ACA subsidies
    • In summary, Medtech & Services is poised to outperform broader markets driven by pricing deals, ACA extension, and strong fundamentals

 

 

ACA (Affordable Care Act also known as Obamacare),
¹ Between September 29 and November 14, 2025: broader equity market (M1WO Index), Healthcare (M1WO0HC Index), and Medtech (M1WO0HE Index)
Source: Bellevue Asset Management

These investment strategies might interest you